This article explores the potential of GLP-1 agonist drugs in treating Alzheimer’s disease (AD) by targeting dysfunctions in all major brain cell types. While some GLP-1 agonists have shown positive cognitive effects, their ability to enter the brain varies, with dulaglutide demonstrating the highest brain penetration and potential for AD treatment. The article emphasizes the need for further clinical trials to determine whether dulaglutide can significantly improve or cure AD.

To read the full article, click here: All GLP-1 Agonists Should, Theoretically, Cure Alzheimers Dementia but Dulaglutide Might Be More Effective Than the Others